Jade Biosciences
JBIO
45 hedge funds and large institutions have $475M invested in Jade Biosciences in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 11 closing their positions.
58% more capital invested
Capital invested by funds: $302M → $475M (+$174M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
0.04% more ownership
Funds ownership: 2.99% → 3.04% (+0.04%)
4% less funds holding
Funds holding: 47 → 45 (-2)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$2.64M |
| 2 |
VA
VR Adviser
New York
|
+$1.67M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.11M |
| 4 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$743K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$415K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$1.2M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$708K |
| 3 |
PL
Parkwood LLC
Cleveland,
Ohio
|
-$438K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$424K |
| 5 |
HF
HRT Financial
New York
|
-$410K |
JBIO Hedge Fund Activity: Q1 2022 in Review
45 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q1 2022, worth a combined $475M — up 58% from $302M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of JBIO and 9 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 15 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $2.64M. The largest seller was Norges Bank, exiting entirely with an estimated $1.2M sold.
- 45 institutional investors held Jade Biosciences (JBIO) as of Q1 2022, down from 47 in Q4 2021.
- Funds reported $475M of Jade Biosciences stock for Q1 2022, up 58% quarter-over-quarter.
- 9 funds opened new Jade Biosciences positions in Q1 2022 and 11 closed out, a net change of -2 holders.
- The largest Jade Biosciences buyer in Q1 2022 was Baker Bros. Advisors, an estimated $2.64M added.
- The largest Jade Biosciences seller in Q1 2022 was Norges Bank, an estimated $1.2M sold.
Based on aggregated 13F filings for Q1 2022.